EGF and metabolic dysfunction-associated steatohepatitis: Rosuvastatin inhibited expression of vascular proliferative factors including EGF, VEGF and PDGF may have an antitumor effect, in addition to its antihyperlipidemic effect, against HCC associated with NASH